PHMMF OTC

Pharma Mar, S.A. is a biopharmaceutical firm dedicated to the discovery, development, manufacturing, and commercialization of bioactive compounds derived from marine organisms, primarily targeting oncology applications. Its products and research initiatives reach across key markets including Spain, Italy, Germany, Ireland, the broader European Union, the United States, and other international territories. The company's operations are structured across three distinct segments: Oncology, Diagnostics, and RNA Interference. Within its oncology portfolio, Pharma Mar markets Yondelis®, prescribed for soft tissue sarcomas and ovarian cancer, alongside Aplidin® for multiple myeloma, and Zepzelca®, which addresses small cell lung cancer. Additionally, the company has PM14, currently undergoing Phase II clinical trials for the treatment of various solid tumors. Beyond oncology, the Diagnostics segment is involved in the development and sale of diagnostic kits. Furthermore, through its RNA Interference division, Pharma Mar is advancing therapeutics designed to modulate or silence gene expression for therapeutic benefit. Established in 1986, the company maintains its headquarters in Madrid, Spain.